Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy.

Egusa M, Saeki I, Takeuchi Y, Shimose S, Ito T, Tani J, Sasaki R, Sasaki K, Hatanaka T, Suzuki T, Kobayashi R, Kakizaki S, Tanabe N, Nishina S, Miyaaki H, Kobara H, Kawashima H, Kawaguchi T, Otsuka M, Yamasaki T, Takami T, Hepatology InVestigator Experts in Japan (HIVE-J) Study Group.

Open source

DOI: 10.1016/j.clnesp.2026.105040
Published: 2026-08-20
Container: Clin Nutr ESPEN
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.clnesp.2026.105040,
  title = {Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy.},
  author = {Egusa M and  Saeki I and  Takeuchi Y and  Shimose S and  Ito T and  Tani J and  Sasaki R and  Sasaki K and  Hatanaka T and  Suzuki T and  Kobayashi R and  Kakizaki S and  Tanabe N and  Nishina S and  Miyaaki H and  Kobara H and  Kawashima H and  Kawaguchi T and  Otsuka M and  Yamasaki T and  Takami T and  Hepatology InVestigator Experts in Japan (HIVE-J) Study Group.},
  year = {2026},
  journal = {Clin Nutr ESPEN},
  doi = {10.1016/j.clnesp.2026.105040},
  url = {https://doi.org/10.1016/j.clnesp.2026.105040}
}

RIS

TY  - JOUR
TI  - Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy.
AU  - Egusa M
AU  -  Saeki I
AU  -  Takeuchi Y
AU  -  Shimose S
AU  -  Ito T
AU  -  Tani J
AU  -  Sasaki R
AU  -  Sasaki K
AU  -  Hatanaka T
AU  -  Suzuki T
AU  -  Kobayashi R
AU  -  Kakizaki S
AU  -  Tanabe N
AU  -  Nishina S
AU  -  Miyaaki H
AU  -  Kobara H
AU  -  Kawashima H
AU  -  Kawaguchi T
AU  -  Otsuka M
AU  -  Yamasaki T
AU  -  Takami T
AU  -  Hepatology InVestigator Experts in Japan (HIVE-J) Study Group.
PY  - 2026
JO  - Clin Nutr ESPEN
DO  - 10.1016/j.clnesp.2026.105040
UR  - https://doi.org/10.1016/j.clnesp.2026.105040
ER  -

APA

M, E., I, S., Y, T., S, S., T, I., J, T., R, S., K, S., T, H., T, S., R, K., S, K., N, T., S, N., H, M., H, K., H, K., T, K., M, O., T, Y., T, T., & Group., H. I. E. I. J. (. S. (2026). Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy.. Clin Nutr ESPEN. https://doi.org/10.1016/j.clnesp.2026.105040

Source records

europe-pmc · retrieved 2026-09-25T23:34:28.342Z